Cancer News and Research

Latest Cancer News and Research

Bionovo enters definitive agreement to raise $3.0 million in registered direct offering

Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.

4 Oct 2010

Vitamin D deficiency in African-American women can increase risk of aggressive breast cancer: Study

African-American women had lower vitamin D levels than white women, and vitamin D deficiency was associated with a greater likelihood for aggressive breast cancer, according to data presented at the Third AACR Conference on the Science of Cancer Health Disparities.

3 Oct 2010

Study shows low DRC level may increase risk for non-melanoma skin cancer

DNA repair capacity (DRC) measurements effectively identified individuals who were at high risk for non-melanoma skin cancer, and may be a useful method to evaluate the efficacy of preventive therapies, according to study results presented at the Third AACR Conference on the Science of Cancer Health Disparities.

3 Oct 2010

Celsion presents Phase I/II DIGNITY trial data at 2010 Breast Cancer Symposium

Celsion Corporation announced today that interim data from its Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium.

3 Oct 2010

Sulindac drug derivative effective in preventing colon cancer: Research

Researchers in the Division of Cancer Prevention, Department of Medicine, at Stony Brook University have discovered that a novel derivative of sulindac, a non-steroidal anti-inflammatory drug (NSAID) known to prevent colon cancer, is more effective and safer than sulindac in preventing colon cancer in animals. The study results are reported in the October issue of the journal Gastroenterology.

3 Oct 2010

Stem cell research breakthrough

Australian researchers have grown new human stem cells outside the body and this may provide new hope to cancer patients and those with genetic disorders. The team found a way to manipulate the environment of blood-forming stem cells to make them multiply.

3 Oct 2010

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial.

1 Oct 2010

Activating rearrangements in receptor genes are more common than previously thought

A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,--an MSKCC surgeon, researcher and the Director of the Brain Tumor Center--and was published in the October 1 issue of the journal Genes & Development.

1 Oct 2010

Elekta releases Atlas-based Autosegmentation 2.0 software for increasing contouring accuracy

Elekta recently launched ABAS (Atlas-based Autosegmentation) 2.0 software, which includes the Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm to increase contouring accuracy. ABAS—considered the industry gold standard for autosegmentation accuracy—deforms atlases of anatomy previously defined on a reference image onto a new patient image, creating a new structure set fit to the patient anatomy and enhancing planning efficiency.

From Elekta 1 Oct 2010

AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system

AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.

1 Oct 2010

BUSM to create Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities

Boston Medical Center (BMC) has been awarded a four year, $5.7 million grant from the National Heart, Lung and Blood Institute (NHLBI) for investigators from Boston University School of Medicine (BUSM) to create the Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities.

1 Oct 2010

Increase in levels of P450 protein creates EET molecules that lower blood pressure

If you are one of the millions of Americans with high blood pressure, more help is on the way. That's because a new research study published in the October 2010 print issue of The FASEB Journal shows that a protein, called P450, metabolizes arachidonic acid in our blood vessel walls to create a tiny molecule with a big name-epoxyeicosatrienoic acid (EET)-which in mice, turns off genes responsible for vascular inflammation and ultimately relaxes blood vessels to lower blood pressure. This protein and genes are also present in humans.

1 Oct 2010

GSA urges treatment of sepsis as a medical emergency

The Global Sepsis Alliance (GSA) is urging healthcare providers, patients and policymakers worldwide to treat sepsis as a medical emergency. "Tens of millions of people die from sepsis each year, making it the likely leading cause of death worldwide. Sepsis kills regardless of age, ethnicity, location and access to care," said Konrad Reinhart, M.D., Chairman of the GSA and director of the Department of Anesthesiology and Intensive Care Medicine, University Hospital of the Friedrich Schiller, University of Jena, Germany.

1 Oct 2010

CDC awards ACS and GWCI $4.25 million to establish National Cancer Survivorship Resource Center

The American Cancer Society (ACS) and the GW Cancer Institute (GWCI) were recently awarded $4.25 million by the Centers for Disease Control (CDC) to establish a National Cancer Survivorship Resource Center. Work on the project will begin on September 30.

1 Oct 2010

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Oct 2010

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

A new report published in the October 2010 print issue of The FASEB Journal offers a ray of hope in the search for new cancer drugs. By examining the seemingly conflicting roles of how oncogenes and tumor suppressor genes handle cellular stress, scientists from the Institute for Advanced Studies in New Jersey argue that each of these opposing systems could be potent drug targets in the effort to stop cancer. In addition, their hypothesis provides new insights into what contributes to immunological disorders such as chronic inflammation and autoimmune diseases.

1 Oct 2010

UC San Diego researcher receives 'Era of Hope Scholar Award' for innovation in breast cancer study

Seth Field, MD, PhD, associate professor in the Department of Medicine at UC San Diego, has been awarded a five-year, $3.86 million "Era of Hope Scholar Award" from the Department of Defense Breast Cancer Research Program. The award supports individuals who have high potential for innovation in breast cancer research early in their careers, researchers considered the "best and brightest" in their field through "extraordinary creativity, vision and productivity and potential for leadership in the breast cancer research community.

1 Oct 2010

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

A study led by researchers at the University of California, San Diego shows that California's 40 year-long tobacco control program has resulted in lung cancer rates that are nearly 25 percent lower than other states.

1 Oct 2010

Report finds development of multiple myeloma is tied to 'hypomethylation'

DNA methylation - a modification of DNA linked to gene regulation - is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).

1 Oct 2010

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

1 Oct 2010

Cancer News and Research

Latest Cancer News and Research

Bionovo enters definitive agreement to raise $3.0 million in registered direct offering

Vitamin D deficiency in African-American women can increase risk of aggressive breast cancer: Study

Study shows low DRC level may increase risk for non-melanoma skin cancer

Celsion presents Phase I/II DIGNITY trial data at 2010 Breast Cancer Symposium

Sulindac drug derivative effective in preventing colon cancer: Research

Stem cell research breakthrough

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Activating rearrangements in receptor genes are more common than previously thought

Elekta releases Atlas-based Autosegmentation 2.0 software for increasing contouring accuracy

AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system

BUSM to create Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities

Increase in levels of P450 protein creates EET molecules that lower blood pressure

GSA urges treatment of sepsis as a medical emergency

CDC awards ACS and GWCI $4.25 million to establish National Cancer Survivorship Resource Center

FDA issues Complete Response Letter for Teva's Neutroval BLA

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

UC San Diego researcher receives 'Era of Hope Scholar Award' for innovation in breast cancer study

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

Report finds development of multiple myeloma is tied to 'hypomethylation'

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Cancer Research - Second Edition eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in